

Synthetic access to some new benzothiazole-based 1,3,4-thiadiazole and 1,3-thiazole derivatives

Kamal M. DAWOOD^{1,*}, Eman A. RAGAB¹, Korany A. ALI²

¹Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt

²Department of Applied Organic Chemistry, Center of Excellence for Advanced Science, National Research Centre, Dokki, Giza, Egypt

Received: 22.03.2015

Accepted/Published Online: 08.08.2015

Final Version: 02.03.2016

Abstract: 1-(Benzothiazol-2-yl)-3-phenylthiourea **2** was prepared and treated with hydrazonoyl chlorides **3a–e** to yield the corresponding 5-(benzothiazol-2-ylimino)-1,3,4-thiadiazole derivatives **6a–e**, respectively. Reaction of the thiourea derivative **2** with ethyl 2-chloro-3-oxobutanoate **9** afforded the corresponding 2-(benzothiazol-2-ylimino)thiazole-5-carboxylate derivative **11**. The newly synthesized heterocyclic derivatives were confirmed from their elemental and spectral analyses.

Key words: Benzothiazole, thiazole, thiadiazole, thiourea, hydrazonoyl chlorides

1. Introduction

1,3,4-Thiadiazoles are among the most common heterocyclic pharmacophores. They display a broad spectrum of biological activities including antimicrobial,¹ anticancer,^{2,3} antioxidant,⁴ antidepressant,⁵ anticonvulsant,^{6,7} and antihypertensive activity,⁸ as well as acetylcholinesterase inhibitors for the treatment of Alzheimer disease.^{9,10} In addition, thiourea derivatives are key synthons for the synthesis of biologically active heterocycles with a broad spectrum of medicinal applications.¹¹ In particular, the most significant thiourea derivatives demonstrated antiviral,¹² anti-HIV,¹³ antifungal,¹⁴ and anticancer activities.¹⁵ Benzothiazolyl thiourea derivatives have also attracted continuing interest due to their valuable biological activities such as antiinflammatory,¹⁶ antibacterial,¹⁷ and cytotoxic activities.^{18,19} As part of our research projects aimed at the synthesis of potent biologically active 1,3,4-thiadiazole-based heterocycles,^{20–32} the aim of this work was the synthesis of some new benzothiazole-based 1,3,4-thiadiazole and 1,3-thiazole derivatives utilizing 1-(benzothiazol-2-yl)-3-phenylthiourea **2** as a key starting synthon.

2. Results and discussion

1-(Benzothiazol-2-yl)-3-phenylthiourea **2** was prepared from the reaction of 2-aminobenzothiazole **1** with phenyl isothiocyanate in dimethylformamide in the presence of potassium hydroxide at room temperature according to literature procedures.^{33,34} First, the reaction of 1-(benzothiazol-2-yl)-3-phenylthiourea **2** with the hydrazonoyl chloride esters **3a–c** was performed. The reaction of **2** with **3a** was carried out in refluxing ethanol in the presence of Et₃N to afford only one isolable product. There are two possible structures, **6a** and **8a**, for the

*Correspondence: dr_dawood@yahoo.com

reaction product either via loss of aniline from intermediate **5a** or via loss of ethanol from the intermediate **7a**, respectively (Scheme 1). The spectral data of the isolated product were completely compatible with structure **6a** and not **8a**. For example, the IR spectrum of **6a** showed a carbonyl absorption band at 1741 cm^{-1} . Its ^1H NMR showed characteristic quartet and triplet signals at δ 1.37 and 4.45 ($J = 7.2\text{ Hz}$) due to ethyl-ester protons in addition to the aromatic protons in the region δ 7.31–7.94. The mass spectrum of **6a** showed the molecular ion at m/z 382. In a similar way, treatment of **2** with the hydrazonoyl chloride esters **3b,c** conducted in refluxing ethanol in the presence of Et_3N afforded the corresponding ethyl 1,3,4-thiadiazole-2-carboxylate derivatives **6b,c** in high yield as shown in Scheme 1.

Next, reaction of the thiourea derivative **2** with the acetyl hydrazonoyl chloride **3d,e** in refluxing ethanol in the presence of triethylamine resulted, similarly, in the formation of only one isolable product as examined by TLC. Structures of the obtained products were established as 5-acetyl-2-(benzothiazol-2-ylimino)-4-aryl-4,5-dihydro-1,3,4-thiadiazoles **6d,e** on the basis of their elemental analyses and spectral data. As outlined in Scheme 1, the loss of aniline molecule from the intermediates **5d,e** led to the formation of compounds **6d,e**. Their IR spectra showed, in each case, an absorption band around 1680 cm^{-1} due to C=O function. The ^1H NMR spectrum of **6e** exhibited two singlet signals at δ 2.22 and 2.52 due to methyl and acetyl protons in addition to the aromatic signals. The mass spectra of **6d,e** showed, in each case, a peak due to their molecular ions.


Finally, treatment of compound **2** with ethyl 2-chloro-3-oxobutanoate (**9**) in refluxing ethanol in the presence of triethylamine yielded a single product for which the structure 5-acetyl-2-(5-acetyl-4-methylthiazol-2-ylimino)-4-methyl-3-phenyl-1,3-thiazole (**11**) was assigned based on its elemental and spectral data. Formation of **11** proceeded via loss of HCl followed by water during an intramolecular cyclization of the intermediate **10**. The presence of only one carbonyl absorption band at 1686 cm^{-1} in the IR spectrum and the presence of three signals at δ 1.33, 2.24, and 4.33 assignable to the CH_3 and $\text{CO}_2\text{CH}_2\text{CH}_3$ protons in the ^1H NMR spectrum of the reaction product supported structure **11** and ruled out the other possible product **13** (Scheme 2). In addition, the mass spectrum of **11** showed a peak at m/z 395 due to its molecular ion.

3. Experimental

Melting points were determined on a Gallenkamp apparatus and are uncorrected. The IR spectra were recorded on Shimadzu FT-IR 8101 PC infrared spectrophotometer. The ^1H NMR spectra were determined in $\text{DMSO}-d_6$ at 300 MHz (^1H NMR) and at 75.46 MHz (^{13}C NMR) on a Varian Mercury VX 300 NMR spectrometer using TMS as an internal standard. Mass spectra were measured on a GCMS-QP1000 EX spectrometer at 70 eV. Elemental analyses were carried out at the Microanalytical Center of Cairo University. Benzothiazolythiourea **2**³³ and hydrazonoyl chlorides **3a-c**,³⁵ and **3d,e**^{36,37} were prepared according to procedures reported in the literature.

4. Synthesis of 5-(benzothiazol-2-ylimino)-4-aryl-1,3,4-thiadiazole derivatives 6a–e


General Procedure. To a stirred solution of 1-(benzothiazol-2-yl)-3-phenylthiourea **2** (0.57 g, 2 mmol) in ethanol (30 ml) was added the appropriate hydrazonoyl chloride **3a-c** or **3d,e** (2 mmol) followed by addition of Et_3N (0.2 mL). The reaction mixture was heated at reflux for 4~7 h, during which the starting substrates were dissolved and completely consumed and a colored product was precipitated. The solid product that formed was filtered off, washed with water and ethanol, dried, and finally recrystallized from the appropriate solvent to afford the corresponding 1,3,4-thiadiazole derivatives **6a-e**, respectively.



Scheme 1. Synthesis of (benzothiazolyl)imino-1,3,4-thiadiazole derivatives 6a-e.

5. Ethyl 5-(benzothiazol-2-ylimino)-4,5-dihydro-4-phenyl-1,3,4-thiadiazole-2-carboxylate (6a)

Yield (0.49 g, 64%), orange solid, mp 210–212 °C (EtOH/DMF); IR (KBr) ν (cm⁻¹): 1741 (C=O), 1592 (C=N), 1530 (C=C); ¹H NMR (DMSO-d₆, 300 MHz) δ 1.37 (t, 3H, CH₂CH₃, *J* = 7.2 Hz), 4.45 (q, 2H, CH₂CH₃, *J* = 7.2 Hz), 7.31 (t, 1H, ArH, *J* = 7.8 Hz), 7.45 (t, 1H, ArH, *J* = 7.8 Hz), 7.52–7.66 (m, 3H, ArH), 7.80–7.94 (m, 4H, ArH); MS *m/z* (%): 382 (M⁺, 92.6), 251 (21.0), 225 (20.4), 198 (18.8), 108 (21.6), 91



Scheme 2. Synthesis of (benzothiazolyl)imino-1,3-thiazolidine derivative **11**.

(100), 77 (76.7). Anal. Calcd. for C₁₈H₁₄N₄O₂S₂ (382.46): C, 56.53; H, 3.69; N, 14.65; S, 16.77. Found: C, 56.27; H, 3.57; N, 14.80; S, 16.72.

6. Ethyl 5-(benzothiazol-2-ylimino)-4,5-dihydro-4-(4-chlorophenyl)-1,3,4-thiadiazole-2-carboxylate (6b)

Yield (0.63 g, 75%), yellow powder, mp 219–221 °C (EtOH/DMF); IR (KBr) ν (cm⁻¹): 1742 (C=O), 1590 (C=N), 1532 (C=C); ¹H NMR (DMSO-d₆, 300 MHz) δ 1.37 (t, 3H, CH₂CH₃, *J* = 7.2 Hz), 4.44 (q, 2H, CH₂CH₃, *J* = 7.2 Hz), 7.32 (t, 1H, ArH, *J* = 7.8 Hz), 7.46 (t, 1H, ArH, *J* = 7.8 Hz), 7.70 (d, 2H, ArH, *J* = 8.7 Hz), 7.87–7.95 (m, 4H, ArH); MS *m/z*(%): 418 (M⁺+2, 41.6), 417 (M⁺+1, 22.9), 416 (M⁺, 96.0), 285 (21.6), 258 (10.2), 192 (8.9), 127 (33.1), 125 (100), 111 (17.2), 90 (24.8), 74 (14.9), 68 (10.2). Anal. Calcd for C₁₈H₁₃ClN₄O₂S₂ (416.90): C, 51.86; H, 3.14; N, 13.44; S, 15.38. Found: C, 52.08; H, 3.11; N, 13.16; S, 15.42.

7. Ethyl 5-(benzothiazol-2-ylimino)-4,5-dihydro-4-(4-tolyl)-1,3,4-thiadiazole-2-carboxylate (6c)

Yield (0.61 g, 77%), yellowish-orange solid, mp 202–204 °C (EtOH/DMF); IR (KBr) ν (cm⁻¹): 1742 (C=O), 1611, 1590 (C=N), 1519 (C=C); ¹H NMR (DMSO-d₆, 300 MHz) δ 1.34 (t, 3H, CH₂CH₃, *J* = 7.2 Hz), 2.42

(s, 3H, CH₃), 4.45 (q, 2H, CH₂CH₃, *J* = 7.2 Hz), 7.24–7.47 (m, 4H, ArH), 7.67 (d, 2H, ArH, *J* = 8.1 Hz), 7.86–7.93 (m, 2H, ArH); MS *m/z*(%): 396 (M⁺, 100), 297 (4.9), 265 (22.1), 239 (14.6), 184 (4.8), 148 (7.2), 105 (97.5), 91 (26.9), 78 (21.6), 65 (18.4). Anal. Calcd for C₁₉H₁₆N₄O₂S₂ (396.49): C, 57.56; H, 4.07; N, 14.13; S, 16.17. Found: C, 57.77; H, 4.16; N, 14.01; S, 16.13.

8. 2-Acetyl-5-(benzothiazol-2-ylimino)-4,5-dihydro-4-phenyl-1,3,4-thiadiazole (6d)

Yield (0.51 g, 72%), yellow solid, mp 222–224 °C (EtOH/DMF); IR (KBr) ν (cm⁻¹): 1686 (C=O), 1595 (C=N), 1534 (C=C); ¹H NMR (DMSO-d₆, 300 MHz) δ 2.64 (s, 3H, COCH₃), 7.32 (t, 1H, ArH, *J* = 7.8 Hz), 7.46 (t, 1H, ArH, *J* = 8.1 Hz), 7.53–7.68 (m, 3H, ArH), 7.86–7.95 (m, 4H, ArH); MS *m/z* (%): 352 (M⁺, 100), 251 (15.1), 225 (10.7), 193 (19.1), 118 (58.1), 117 (14.3), 108 (12.6), 91 (73.2), 77 (47.9). Anal. Calcd for C₁₇H₁₂N₄OS₂ (352.43): C, 57.93; H, 3.43; N, 15.90; S, 18.20. Found: C, 57.77; H, 3.32; N, 15.66; S, 18.28.

9. 2-Acetyl-5-(benzothiazol-2-ylimino)-4,5-dihydro-4-(4-tolyl)-1,3,4-thiadiazole (6e)

Yield (0.51 g, 70%), yellow solid, mp 233–235 °C (EtOH/DMF); IR (KBr) ν (cm⁻¹): 1679 (C=O), 1586 (C=N), 1541 (C=C); ¹H NMR (DMSO-d₆, 300 MHz) δ 2.22 (s, 3H, p-CH₃), 2.52 (s, 3H, COCH₃), 7.23 (t, 1H, ArH, *J* = 7.2 Hz), 7.39 (t, 1H, ArH, *J* = 7.5 Hz), 7.57 (d, 2H, ArH, *J* = 8.8 Hz), 7.65 (d, 2H, ArH, *J* = 8.5 Hz), 7.78–7.84 (m, 2H, ArH); MS *m/z* (%): 366 (M⁺, 7.1), 287 (13.7), 194 (26.1), 132 (27.5), 104 (11.8), 85 (100). Anal. Calcd for C₁₈H₁₄N₄OS₂ (366.46): C, 58.99; H, 3.85; N, 15.29; S, 17.50. Found: C, 58.78; H, 3.77; N, 15.12; S, 17.54.

10. Ethyl 2-(benzothiazol-2-ylimino)-4-methyl-3-phenyl-2,3-dihydrothiazole-5-carboxylate (11)

To a stirred solution of 1-(benzothiazol-2-yl)-3-phenylthiourea **2** (0.57 g, 2 mmol) in ethanol (30 mL), ethyl 2-chloro-3-oxobutanoate (**9**) (2 mmol) was added followed by adding Et₃N (0.2 mL) and the mixture was then heated at reflux for 4 h. The solvent was removed under reduced pressure and the residue was treated with crushed ice; then the precipitate was filtered off, washed with water and ethanol, dried, and finally recrystallized from DMF to give the corresponding 1,3-thiazole-5-carboxylate derivative **11**. Yield (0.55 g, 69%), yellowish-green solid, mp 206–208 °C (DMF); IR (KBr), ν g (cm⁻¹): 1686 (C=O), 1594 (C=N), 1506 (C=C); ¹H NMR (DMSO-d₆, 300 MHz) δ 1.33 (t, 3H, CH₂CH₃, *J* = 7.2 Hz), 2.24 (s, 3H, CH₃), 4.33 (q, 2H, CH₂CH₃, *J* = 7.2 Hz), 7.23 (t, 1H, ArH, *J* = 7.8 Hz), 7.39 (t, 1H, ArH, *J* = 7.8 Hz), 7.51–7.64 (m, 5H, ArH), 7.78–7.84 (m, 2H, ArH). ¹³C NMR (DMSO-d₆, 75.46 MHz) δ 13.9, 14.4, 32.4, 61.0, 64.8, 118.1, 120.6, 121.2, 121.8, 122.8, 124.6, 128.5, 129.4, 138.0, 146.9, 155.9, 168.6, 172.6. MS *m/z*(%): 395 (M⁺, 51.5), 323 (12.5), 253 (20.7), 225 (10.8), 135 (12.9), 118 (66.7), 77 (100). Anal. Calcd for C₂₀H₁₇N₃O₂S₂ (395.49): C, 60.74; H, 4.33; N, 10.62; S, 16.22. Found: C, 60.65; H, 4.29; N, 10.39; S, 16.27%.

References

1. Padmavathi, V.; Reddy, G. S.; Padmaja, A.; Kondaiiah, P.; Shazia, A. *Eur. J. Med. Chem.* **2009**, *44*, 2106–2112.
2. Dawood, K. M.; Eldebss, T. M. A.; El-Zahabi, H. S.; Yousef, M. H.; Metz, P. *Eur. J. Med. Chem.* **2013**, *70*, 740–749.
3. Juszczak, M.; Matysiak, J.; Szeliga, M.; Pozarowski, P.; Rzeski, W. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 5466–5469.

4. Khan, I.; Ali, S.; Hameed, S.; Rama, N. H.; Hussain, M. T.; Wadood, A.; Uddin, R.; Ul-Haq, Z.; Khan, A.; Ali, S.; et al. *Eur. J. Med. Chem.* **2010**, *45*, 5200–5207.
5. Jubie, S.; Ramesh, P. N.; Dhanabal, P.; Kalirajana, R.; Murugananthamb, N.; Antony, A. S. *Eur. J. Med. Chem.* **2012**, *54*, 931–935.
6. Dawood, K. M.; Abdel-Gawad, H.; Ragab, E. A.; Ellithey, M.; Mohamed, H. A. *Bioorg. Med. Chem.* **2006**, *14*, 3672–3680.
7. Harish, K. P.; Mohana, K. N.; Mallesha, L. S. *Drug Invent. Today* **2013**, *5*, 92–99.
8. Hasui, T.; Matsunaga, N.; Ora, T.; Ohyabu, N.; Nishigaki, N.; Imura, Y.; Igata, Y.; Matsui, H.; Motoyaji, T.; Habuka, N.; et al. *J. Med. Chem.* **2011**, *54*, 8616–8631.
9. Skrzypek, A.; Matysiak, J.; Karpinska, M. M.; Niewiadomy, A. *Enzyme Inhib. Med. Chem.* **2013**, *28*, 816–823.
10. Skrzypek, A.; Matysiak, J.; Niewiadomy, A.; Bajda, M.; Szymanski, P. *Eur. J. Med. Chem.* **2013**, *62*, 311–319.
11. Dhooghe, M.; De Kime, N. *Tetrahedron* **2006**, *62*, 513–536.
12. Galabov, A. S.; Galabov, B. S.; Neykova, N. A. *J. Med. Chem.* **1980**, *23*, 1048–1051.
13. Hunter, R.; Younis, Y.; Muhanji, C. I.; Curtin, T. L.; Naidoo, K. J.; Petersen, M.; Bailey, C. M.; Basavapathruni, A.; Anderson, K. S. *Bioorg. Med. Chem.* **2008**, *16*, 10270–10280.
14. Abdel-Aziem, A.; El-Gendy, M. S.; Abdelhamid, A. O. *Eur. J. Chem.* **2012**, *3*, 455–460.
15. Lv, P. C.; Li, H. Q.; Sun, J.; Zhou, Y.; Zhu, H. L. *Bioorg. Med. Chem.* **2010**, *18*, 4606–4614.
16. Bahekar, S. S.; Shinde, D. B. *J. Korean Chem. Soc.* **2003**, *47*, 237–240.
17. Saeed, A.; Rafique, H.; Hameed, A.; Rasheed, S. *Pharm. Chem. J.*, **2008**, *42*, 191–195.
18. Kumbhare, R. M.; Dadmal, T.; Kosurkar, U.; Sridhar, V.; Rao, J. V. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 453–455.
19. Abdel-Rahman, H. M.; Morsy, M. A. *J. Enzym. Inhib. Med. Chem.* **2007**, *22*, 57–64.
20. Dawood, K. M.; Abu-Deif, H. K. *Chem. Pharm. Bull.* **2014**, *62*, 439–445.
21. Dawood, K. M.; Abu-Deif, H. K. *Eur. J. Chem.* **2013**, *4*, 277–284.
22. Dawood, K. M.; Abdel-Gawad, H.; Mohamed, H. A.; Badria, F. A. *Med. Chem. Res.* **2011**, *20*, 912–919.
23. Hegazi, B.; Mohamed, H. A.; Dawood, K. M.; Badria, F. A. R. *Chem. Pharm. Bull.* **2010**, *58*, 479–483.
24. Abdel-Gawad, H.; Mohamed, H. A.; Dawood, K. M.; Badria, F. A. R. *Chem. Pharm. Bull.* **2010**, *58*, 1529–1531.
25. Dawood, K. M.; Ragab, E. A.; Farag, A. M. *Phosphorus, Sulfur and Silicon* **2010**, *185*, 1796–17802.
26. Dawood, K. M.; Raslan, M. A. *J. Heterocycl. Chem.* **2008**, *45*, 137–141.
27. Dawood, K. M.; Farag, A. M.; Abdelaziz, H. A. *Heteroatom Chem.* **2007**, *18*, 294–300.
28. Dawood, K. M.; Farag, A. M.; Abdelaziz, H. A. *Heteroatom Chem.* **2005**, *16*, 621–627.
29. Farag, A. M.; Dawood, K. M.; Elmenoufy, H. A. *Heteroatom Chem.* **2004**, *15*, 508–514.
30. Dawood, K. M.; Ragab, E. A.; Farag, A. M. *J. Chem Res.* **2003**, (S) 685–586, (M) 1151–1160.
31. Dawood, K. M.; Raslan, M. A.; Farag, A. M. *Synth. Commun.* **2003**, *33*, 4079–4086.
32. Kandeel, Z. E.; Dawood, K. M.; Ragab, E. A.; Farag, A. M. *Heteroatom Chem.* **2002**, *13*, 248–251.
33. Glotova, T. E.; Dvorko, M. Yu.; Albanov, A. I.; Kazheva, O. N.; Shilov, G. V.; D'yachenko, O. A. *Russ. J. Org. Chem.* **2008**, *44*, 1532–1537.
34. Kumbhare, R. M.; Dadmal, T.; Kosurkar, U.; Kumar, K. V. *J. Heterocyclic Chem.* **2012**, *49*, 342–348.
35. Hegarty, A. F.; Cashman, M. P.; Scott, F. L. *Chem. Commun.* **1971**, 684–685.
36. Dieckmann, W.; Platz, L. *Ber. Dtsch Chem. Ges.* **1906**, *38*, 2989–2995.
37. Eweiss, N. F.; Abdelhamid, A. O. *J. Heterocycl. Chem.* **1980**, *17*, 1713–1717.

Copyright of Turkish Journal of Chemistry is the property of Scientific and Technical Research Council of Turkey and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.